Though Moderna stock soared back then, in more recent times, the stock has stumbled. The company has seen vaccine sales ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the afternoon session after the broader biotech sector experienced a strong rebound, lifting shares of companies within the industry.

Since that moment, Moderna has taken steps to pave the path to long-term growth -- from cutting costs to focusing on its vast pipeline. Considering the full picture, now, with the stock down 80% over ...

Moderna earns the No. 356 rank among its peers in the Medical-Biomed/Biotech industry group. Exact Sciences EXAS, Genmab ADR GMAB and Krystal Biotech KRYS are among the top 5 highly rated stocks ...

On Monday, Moderna MRNA provided an update on its financial outlook and pipeline progress at the J.P. Morgan Healthcare Conference. At the conference, the company lowered its previously issued sales ...

A bad seven-month stretch just got worse for Moderna (NASDAQ: MRNA). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday. This ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. This might not be enough to turn around the fortunes of the developer of go-to COVID-19 ...

Moderna, Inc. has rallied ~23%, but rated a Sell due to deteriorating fundamentals. Learn more about MRNA stock here.

Goldman Sachs analyst Salveen Richter downgrades Moderna from Buy to Neutral and lowers the price target from $99 to $51. The analyst expects Moderna to report product revenue at the low end of its ...

Moderna on Monday lowered its 2025 sales guidance by roughly $1 billion due to a few potential headwinds later this year, as the biotech company continues to cut costs and expand its portfolio.

After donating $176 million in proceeds from his original stock options in 2023, Stéphane Bancel is taking a different path ...